• Je něco špatně v tomto záznamu ?

Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats

V.C. Chabova, H.J. Kramer, I. Vaneckova, Z. Vernerova, V. Eis, V. Tesar, P. Skaroupkova, M. Thumova, S. Schejbalova, Z. Huskova, Z. Vanourkova, A. Kolsky, J.D. Imig, L. Cervenka

. 2007 ; 47 (2-3) : 145-159.

Jazyk angličtina Země Spojené státy americké

Perzistentní odkaz   https://www.medvik.cz/link/bmc10013274

Grantová podpora
NR8271 MZ0 CEP - Centrální evidence projektů

The aim of the present study was to evaluate the effects of inhibition of cytochrome P-450 (CYP) activity by 1-aminobenzotriazole (ABT) and by CoCl(2), first, on the development of hypertension when treatment was started in young male heterozygous Ren-2 transgenic rats (TGR) and, second, on blood pressure (BP) when treatment was started in adult TGR with established hypertension. Normotensive Hannover Sprague-Dawley (HanSD) rats served as controls. In addition, the renal cortical activities of omega-hydroxylase, the enzyme catalyzing the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), and of epoxygenase, the enzyme responsible for epoxyeicosatrienoic acids (EETs) production, and urinary excretion of 20-HETE and EETs in TGR and HanSD rats were assessed. TGR have higher renal tissue omega-hydroxylase activity and urinary excretion of 20-HETE but have significantly lower renal epoxygenase activity and urinary excretion of EETs than HanSD rats. Treatment of young TGR with ABT and CoCl(2) attenuated the development of hypertension and cardiac hypertrophy and prevented glomerulosclerosis. Administration of ABT and CoCl(2) in adult TGR decreased BP, cardiac hypertrophy, but did not reduce glomerulosclerosis. Our data suggest that altered production and/or action of CYP-derived metabolites play a permissive role in the development and maintenance of hypertension in TGR by enhancing ANG II-induced vasoconstriction.

000      
03892naa 2200649 a 4500
001      
bmc10013274
003      
CZ-PrNML
005      
20131010082954.0
008      
100602s2007 xxu e eng||
009      
AR
040    __
$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Čertíková-Chábová, Věra $7 xx0095872
245    10
$a Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats / $c V.C. Chabova, H.J. Kramer, I. Vaneckova, Z. Vernerova, V. Eis, V. Tesar, P. Skaroupkova, M. Thumova, S. Schejbalova, Z. Huskova, Z. Vanourkova, A. Kolsky, J.D. Imig, L. Cervenka
314    __
$a Department of Nephrology, 1st Medical Faculty, Charles University, Prague, Czech Republic
520    9_
$a The aim of the present study was to evaluate the effects of inhibition of cytochrome P-450 (CYP) activity by 1-aminobenzotriazole (ABT) and by CoCl(2), first, on the development of hypertension when treatment was started in young male heterozygous Ren-2 transgenic rats (TGR) and, second, on blood pressure (BP) when treatment was started in adult TGR with established hypertension. Normotensive Hannover Sprague-Dawley (HanSD) rats served as controls. In addition, the renal cortical activities of omega-hydroxylase, the enzyme catalyzing the formation of 20-hydroxyeicosatetraenoic acid (20-HETE), and of epoxygenase, the enzyme responsible for epoxyeicosatrienoic acids (EETs) production, and urinary excretion of 20-HETE and EETs in TGR and HanSD rats were assessed. TGR have higher renal tissue omega-hydroxylase activity and urinary excretion of 20-HETE but have significantly lower renal epoxygenase activity and urinary excretion of EETs than HanSD rats. Treatment of young TGR with ABT and CoCl(2) attenuated the development of hypertension and cardiac hypertrophy and prevented glomerulosclerosis. Administration of ABT and CoCl(2) in adult TGR decreased BP, cardiac hypertrophy, but did not reduce glomerulosclerosis. Our data suggest that altered production and/or action of CYP-derived metabolites play a permissive role in the development and maintenance of hypertension in TGR by enhancing ANG II-induced vasoconstriction.
650    _2
$a cytochrom P450 CYP4A $x metabolismus $7 D042926
650    _2
$a zvířata $7 D000818
650    _2
$a krevní tlak $x účinky léků $7 D001794
650    _2
$a kardiomegalie $x patofyziologie $7 D006332
650    _2
$a kobalt $7 D003035
650    _2
$a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a inhibitory enzymů $x farmakologie $7 D004791
650    _2
$a fokálně segmentální glomeruloskleróza $x patofyziologie $7 D005923
650    _2
$a heterozygot $7 D006579
650    _2
$a kyseliny hydroxyeikosatetraenové $x biosyntéza $7 D006893
650    _2
$a hypertenze $x patofyziologie $7 D006973
650    _2
$a kůra ledviny $7 D007672
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a oxygenasy $x metabolismus $7 D010105
650    _2
$a náhodné rozdělení $7 D011897
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a potkani Sprague-Dawley $7 D017207
650    _2
$a renin $x genetika $x metabolismus $7 D012083
650    _2
$a renin-angiotensin systém $x fyziologie $7 D012084
650    _2
$a triazoly $x farmakologie $7 D014230
650    _2
$a vazokonstrikce $7 D014661
650    _2
$a financování organizované $7 D005381
650    _2
$a inhibitory cytochromu P450 $7 D065607
700    1_
$a Kramer, Herbert J. $7 xx0085908
700    1_
$a Vaněčková, Ivana, $d 1964- $7 xx0030586
700    1_
$a Vernerová, Zdenka, $d 1960-2020 $7 jo2002104672
700    1_
$a Eis, Václav $7 xx0063835
700    1_
$a Tesař, Vladimír, $d 1957- $7 jn20000402349
700    1_
$a Škaroupková, Petra $7 xx0117683
700    1_
$a Thumová, Monika. $7 _AN037603
700    1_
$a Schejbalová, Stanislava $7 xx0134795
700    1_
$a Husková, Zuzana, $d 1978- $7 xx0074206
700    1_
$a Vaňourková, Zdeňka, $d 1973- $7 xx0074217
700    1_
$a Kolský, Alexander $7 xx0081836
700    1_
$a Imig, John D. $7 _AN055124
700    1_
$a Červenka, Luděk, $d 1967- $7 xx0037105
773    0_
$t Vascular Pharmacology $w MED00008593 $g Roč. 47, č. 2-3 (2007), s. 145-159 $x 1537-1891
910    __
$a ABA008 $b x $y 7 $z 0
990    __
$a 20110413111255 $b ABA008
991    __
$a 20131010083517 $b ABA008
999    __
$a ok $b bmc $g 749140 $s 612769
BAS    __
$a 3
BMC    __
$a 2007 $b 47 $c 2-3 $d 145-159 $i 1537-1891 $m Vascular pharmacology $n Vascul Pharmacol $x MED00008593
GRA    __
$a NR8271 $p MZ0
LZP    __
$a 2010-B2/ipme

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...